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Decreaseofbonemineraldensity(BMD)andfractureriskisincreasedinmenwithprostatecancerreceivingandrogendeprivation
therapy (ADT). We looked at possible predictors of decreased BMD and increased fracture risk in men with prostate cancer; most
of whom were on ADT. In a retrospective study, we analyzed serum, BMD, and clinical risk factors used in the Fracture Risk
Assessment (FRAX) tool and others in 78 men with prostate cancer with reported height loss. The subjects were divided in two
groups: 22 men with and 56 without vertebral fractures. 17 of the 22 men with vertebral fractures on spine X-rays did not know
they had a vertebral fracture. Of those 17 men, 9 had not previously qualiﬁed for treatment based on preradiograph FRAX score
calculated with BMD, and 6 based on FRAX calculated without BMD. Performing spine ﬁlms increased the predictive ability of
FRAX for vertebral fracture. Vertebral fracture was better predicted by FRAX for other osteoporotic fractures than FRAX for hip
fractures.TheinclusionofBMDinFRAXcalculationsdidnotaﬀectthepredictiveabilityofFRAX.ThePSAlevelshowedapositive
correlation with lumbar spine BMD and accounted for about 9% of spine BMD.
1.Introduction
220,000 men are diagnosed with prostate cancer each year,
and more than 40 percent receive androgen deprivation
therapy (ADT) as initial treatment [1, 2]. ADT has been
shown to decrease bone mineral density (BMD) as measured
by dual-energy X-ray absorptiometry (DXA) as well as
increase risk of fracture. After initiating ADT, BMD decline
starts shortly after [3, 4]. A meta-analysis of almost 117,000
men demonstrated that patients on ADT had lower total
BMD,30%increasedriskofosteoporosis,and70%increased
risk of fractures [5]. In a study of over 47,000 men with
prostate cancer by the National Cancer Institute (NCI) and
Medicare, those treated with ADT or bilateral orchiectomy
within six months of diagnosis had a 5-year fracture risk
of 19.4% versus 12.6% in controls matched for patient and
tumor characteristics [6]. A systematic review of ﬁve studies
on prostate cancer patients in the US and abroad, which
included the NCI-Medicare study, found a 23% increase in
fracture risk for men treated with ADT [7].
Fracture Risk Assessment (FRAX) is an algorithm devel-
oped by the World Health Organization to determine
fracture risk of men and women [8]. The risk factors in
the algorithm include age, current height, prior fracture,
parental history of fracture, BMD of the femoral neck, and
secondary osteoporosis risk factors such as hypogonadism.
Yet, inclusion of secondary causes such as hypogonadism
does not change FRAX-calculated risk of fracture when
femoral neck BMD is included. The National Osteoporosis
Foundation’s recommended treatment thresholds based on
FRAX score are 3% for hip (“Hip FRAX”) and 20% for
major osteoporotic fractures (“Osteoporotic FRAX”) [9].2 Journal of Osteoporosis
Prior studies of men with prostate cancer on ADT by
Saylor et al. and Adler et al. [10, 11] demonstrated that the
inclusionofBMDvaluesintheFRAXcalculationledtolower
FRAX scores, and thus fewer people qualiﬁed for treatment.
These studies also found that the majority of men who met
treatment thresholds did so because of the hip FRAX rather
than osteoporotic FRAX. Men younger than 70 [10]a n d
of African-American ethnicity [11] were less likely to meet
treatment thresholds.
Prior studies have addressed factors that aﬀect treatment
qualiﬁcations in men on ADT based on FRAX scores. The
utility FRAX for predicting incidence of fracture in men
with prostate cancer has yet to be determined. Many of
vertebral fractures are clinically unrecognized due to lack
of complaints, yet, they are strong predictors of future
fractures at all sites. Two and half inches or greater height
loss in men is associated with increased risk of vertebral
compression fractures [12]. The utility of height loss in
predicting vertebral fracture in men with prostate cancer has
not been established.
2.MaterialsandMethods
2.1. Subjects. This was a retrospective study of 78 male
patients with prostate cancer (median age 77: 55 Caucasian,
19 African-American, 3 Hispanic, and 1 Spanish) at the
Dallas Veterans Aﬀair Medical center (DVAMC) approved by
the Institutional Review Board of DVAMC, Dallas, Tex, USA.
Subjects had been referred to the Osteoporosis Clinic by
the Department of Urology for management of bone health,
either while receiving ADT (N =63) or before initiating
ADT (N =15). All men at DVAMC receiving ADT or about
to initiate ADT are referred by Urology Department to
Osteoporosis clinic regardless of whether they have history
of osteoporosis. At initial visit at Osteoporosis clinic, spine
X-rays are obtained on all patients whose measured height in
clinic is at least one inch less than their self-reported young
adult height. Inclusion criteria were height loss and having
spineX-rays,whichwereperformednearoratthetimeofthe
initial Osteoporosis Clinic visit. Height loss was determined
by the height measured at the initial Osteoporosis Clinic
visit compared to self-reported young adult height. Patients
with pathologic fractures thought to be secondary to bone
metastases were excluded. The primary outcome of the study
w a sw h e t h e rh e i g h tl o s sp r e d i c t e df r a c t u r ea n dB M Di n
men with prostate cancer on ADT. Secondary endpoints:
in how many men would FRAX score change with ﬁnding
compression fracture on spine X-ray, and if the duration
of ADT and level of prostate-speciﬁc antigen (PSA) could
predict BMD and fractures at any site.
2.2. Statistical Analysis. Comparisons of subjects with and
without vertebral fractures were made with the Wilcoxon
Rank Sum test. Univariate associations between continuous
variables were assessed with Spearman correlation coeﬃ-
cients. Logistic regression analysis was used to assess pre-
dictors of fractures and to estimate unadjusted and adjusted
odds ratios for fracture risk. Multiple linear regression
analysis was conducted to further evaluate the relationship
between spine BMD as the dependent variable and PSA
while controlling for age, weight, and use of vitamin D
supplements. Data with positively skewed distributions were
log-transformed prior to parametric analysis. Statistical
analysis was performed with SAS version 9.2 (SAS Institute,
Cary, NC, USA).
To assess the utility of FRAX scores in predicting of
vertebral fractures, receiver operating characteristic (ROC)
curves which plot 1-speciﬁcity versus the sensitivity of the
diagnostic value of the model were constructed, and the
area under these curves (AUC) and 95% conﬁdence intervals
were calculated. An ROC AUC of 0.5 indicates chance
p e r f o rm a n c e ,a n da nR OCA U Co f1 . 0i st h ei d e a l ,m a x i m u m
AUC [13].
2.3. Radiography/Laboratory Measurements. BMD of the fe-
moral neck, total hip, and lumbar spine were measured by
DXA (Hologic QDR 4500A, Waltham, Mass, USA) in the
DVAMCNuclearMedicineDepartment.Theleastsigniﬁcant
change in g/cm2 for regions of interest in grams per square
centimeterwasasfollowslumbarspine0.031,totalhip0.037,
and femoral neck 0.029. Serum total testosterone was mea-
sured by electrochemiluminescence immunoassay, alkaline
phosphatase by the p-nitrophenyl phosphate method, 25-
hydroxy vitamin D by liquid chromatography/tandem mass
spectrometry, PTH by chemiluminescent immunoassay, and
calcium by indirect potentiometry. Intra-assay coeﬃcients of
variationforalloftheassayswerelessthanthreepercent,and
interassay coeﬃcients of variation were less than 8 percent.
3. Results and Discussion
At baseline, men with prostate cancer, with or without
vertebral fracture, were not statistically diﬀerent, except for
total testosterone levels and FRAX scores (Table 1).
Testosterone levels between groups were statistically dif-
ferent (P=0.01), yet, levels in both groups were profoundly
low. The FRAX scores for hip fractures and other osteo-
porotic fractures were also statistically diﬀerent (Table 2), as
expected,whenmenwithvertebralfracturesandnovertebral
fractures were compared.
None of the primary outcomes were positive. The mean
diﬀerence of height loss between men with and without
vertebral fractures group was only −0.19cm (95% CI: −0.83
to 0.45). Degree of height loss did not predict either bone
densityorfracturesatanysite;riskofvertebralfracturebased
on height loss produced an odds ratio of 1.1 (95% CI: 0.76 to
1.65). This can likely be explained by our inclusion criteria.
In our clinic we order spine X-rays in men who have lost
more than one inch of height, and, therefore, we could not
compare men with and without height loss.
Yet, 17 of the 22 subjects with vertebral fractures had
no known history of vertebral fracture until they were
discovered incidentally on spine ﬁlms ordered due to a loss
of height. Had these fractures not been detected by spine X-
rays, nine (about 41%) of the 22 men with fractures would
have not qualiﬁed for treatment based on FRAX calculated
with BMD or six (about 27%) based on FRAX calculated
without BMD.Journal of Osteoporosis 3
Table 1: Baseline characteristics stratiﬁed by presence of vertebral fracture.
No vertebral fracture Vertebral fracture
n=56 n=22
Variable Median Mean SD Range Median Mean SD Range P value∗
Duration of ADT (months) 16.5 39.6 44.7 0.0–10.5 10.5 30.3 43.5 0.0–156.0 0.21
Age (years) 77.0 76.5 8.2 58.0–77.5 77.5 78.0 6.7 63.0–88.0 0.53
Weight (kg) 83.5 84.8 17.1 54.5–86.7 86.7 87.1 18.0 54.8–119.8 0.46
Height (cm) 172.7 171.7 6.1 152.4–171.4 171.4 172.5 7.1 157.5–182.9 0.83
Height loss (cm) 5.1 5.8 3.0 0.8–5.8 5.8 6.4 3.6 1.3–14.0 0.58
BMI (kg/m2) 28.4 28.5 4.9 18.2–28.6 28.6 28.7 5.5 18.3–40.4 0.76
25-(OH) Vitamin D (ng/mL) 31.1 30.3 14.6 7.0–26.1 26.1 27.1 10.9 8.0–57.8 0.42
Serum calcium (mg/dL) 9.7 9.5 1.3 0.7–9.6 9.6 9.5 0.5 7.9–10.6 0.52
Parathyroid hormone (pg/mL) 44.0 49.5 28.1 16.7–37.3 37.3 45.9 28.8 15.8–135.0 0.49
Alkaline phosphatase (U/L) 80.0 92.4 80.6 49.0–73.0 73.0 74.2 17.0 47.0–112.0 0.16
Prostate-speciﬁc antigen (PSA) (ng/mL) 0.3 6.2 15.1 0.1–0.3 0.3 2.8 6.7 0.1–30.7 0.49
Testosterone (ng/mL) 0.1 0.6 1.3 0.1–0.2 0.2 1.4 1.7 0.1–5.9 0.01
∗P values are from the Wilcoxon rank sum test.
Table 2: BMD and FRAX stratiﬁed by presence of vertebral fracture.
No vertebral fracture Vertebral fracture
n=56 n=22
Variable Median Mean SD Range Median Mean SD Range P-value∗
BMD, femoral neck 0.7 0.7 0.1 0.5–1.0 0.7 0.7 0.1 0.5–0.9 0.34
Ts c o r e ,f e m o r a ln e c k −1.8 −1.9 0.7 −3.3–−0.7 −2.2 −2.0 0.8 −3.4–−0.6 0.33
BMD, total hip 0.9 0.9 0.1 0.6–1.2 0.8 0.8 0.2 0.5–1.2 0.22
T score, total hip −1.2 −1.3 0.9 −3.0–0.3 −1.4 −1.5 1.1 −3.7–0.0 0.51
BMD, lumbar spine 1.0 1.0 0.2 0.8–1.6 0.9 0.9 0.2 0.5–1.3 0.11
T score, lumbar spine −1.1 −0.9 1.6 −4.0–4.6 −1.8 −1.6 1.8 −5.2–2.1 0.10
FRAX (Osteo) without BMD (%) 9.3 10.8 6.2 1.8–33.0 15.0 16.0 6.8 6.8–31.0 0.001
FRAX (Hip) without BMD (%) 4.0 5.5 4.8 0.1–24.0 6.8 8.1 6.0 1.7–25.0 0.03
FRAX (Osteo) with BMD (%) 7.5 9.5 6.9 1.9–33.0 11.0 14.0 7.8 5.4–41.0 0.002
FRAX (Hip) with BMD (%) 3.0 4.5 5.1 0.1–28.0 4.5 6.6 7.1 1.1–36.0 0.03
∗P values are from the Wilcoxon rank sum test.
BMD measurements are in g/cm2.
Table 3: Summary of multiple regression analysis for variables predicting spine bone mineral density.
Variable PSA∗ Age Weight Vitamin D supplement Race R2
Model 1 B( S E ) 0.02 (0.01) — — — — 0.06
P 0.03 — — — —
Model 2 B( S E ) 0.02 (0.01) 0.005 (0.003) — — — 0.08
P 0.05 0.08 — — —
Model 3 B( S E ) 0.02 (0.01) 0.005 (0.003) 0.0007 (0.0005) — — 0.09
P 0.05 0.04 0.17 — —
Model 4 B( S E ) 0.02 (0.01) 0.004 (0.002) — −0.13 (0.04) — 0.22
P 0.045 0.12 — 0.001 —
Model 5 B( S E ) 0.02 (0.01) 0.004 (0.002) — −0.12 (0.04) 0.04 (0.04) 0.23
P 0.05 0.13 — 0.001 0.33
Model 6 B( S E ) 0.02 (0.01) 0.004 (0.003) 0.0004 (0.0005) −0.12 (0.04) — 0.23
P 0.04 0.04 0.40 0.003 —
B = regression coeﬃcient, SE = standard error.
∗loge transformed PSA.
Race is modeled as African-American versus non-African-American.4 Journal of Osteoporosis
Table 4: FRAX score in the prediction of vertebral fracture in men with prostate cancer.
All Subjects Non-African-American African-American
(N =78; vertebral (N =59; vertebral (N =19; vertebral
Fx=22/78=24.4%) Fx=18/59=31%) Fx=4/19=21%)
ROC AUC 95% CI ROC AUC 95% CI ROC AUC 95% CI
FRAX (Hip)
without BMD before X-ray 0.55 0.39–0.70 0.59 0.42–0.77 0.42 0.15–0.70
after X-ray 0.66 0.53–0.78 0.63 0.47–0.78 0.72 0.42–1.00
FRAX (Osteo)
without BMD before X-ray 0.59 0.43–0.75 0.66 0.48–0.84 0.50 0.22–0.78
after X-ray 0.74 0.62–0.85 0.73 0.59–0.87 0.94 0.82–1.00
FRAX (Hip)
with BMD before X-ray 0.53 0.37–0.69 0.60 0.42–0.79 0.64 0.18–1.00
after X-ray 0.66 0.52–0.80 0.63 0.47–0.79 0.74 0.39–1.00
FRAX (Osteo)
with BMD before X-ray 0.54 0.38–0.69 0.62 0.43–0.82 0.69 0.30–1.00
after X-ray 0.72 0.60–0.84 0.70 0.55–0.84 0.95 0.84–1.00
ROC: receiver operating characteristic; AUC: area under the curve; CI: conﬁdence interval.
BMD: Bone mineral density; Osteo: osteoporotic.
Discovery of incidental vertebral fractures on spine ﬁlms
increased the predictive ability for vertebral fracture of all
types of FRAX scores: hip FRAX with or without BMD and
osteoporotic FRAXwithorwithoutBMD(Table 4).Allpost-
X-ray hip FRAX and osteoporotic FRAX were statistically
signiﬁcant (AUC signiﬁcantly diﬀerent from null of 0.50).
Osteoporotic FRAX demonstrated greater predictive ability
for vertebral fracture than hip FRAX, 0.74 versus 0.66 AUC,
respectively, without BMD (P=0.01) and 0.72 versus 0.66
AUC, respectively, with BMD (P=0.04). The ROC models
for predictive ability of FRAX were not signiﬁcantly changed
by including a factor accounting for whether the patient was
already on ADT. Thus, data for all 78 patients (63 already on
ADT, 15 not on ADT) is displayed.
The inclusion of BMD in FRAX calculations did not
aﬀect the predictive ability of FRAX. FRAX scores calculated
with and without BMD were signiﬁcantly related (Table 2).
Spearmancorrelationcoeﬃcientswererho=0.80(P<0.001)
for osteoporotic FRAX (Figure 1(a))a n dr h o=0.71 for hip
FRAX (P<0.001) (Figure 1(b)).
There were too few fractures in the African-American
group to give adequate precision so conclusions cannot
be reliably drawn from the African-American-speciﬁc data.
ROC AUC appears high in AAs because of high speciﬁcity
due to low incidence of vertebral fracture (Table 4). Race
was not correlated with spine BMD in multivariate linear
regression models controlling for age, PSA level, and use
of vitamin D supplementation. The PSA level showed a
positive correlation with lumbar spine BMD (Figure 2)i n
both the univariate linear regression model (P=0.03) and
the multivariate linear regression models controlling for age,
weight, and use of vitamin D supplements (P=0.04), as
displayed in Table 3, and accounted for about 9% of spine
BMD. Weight correlated with BMD in the spine (rho=0.25,
P=0.03),femoralneck(rho=0.43,P<0.0001),andtotalhip
(rho=0.43, P=0.0001) (data not shown). Age had a positive
correlation with BMD at lumbar spine (P<0.02) but not at
femoral neck or total hip.
From other secondary outcomes, neither duration of
ADT, level of 25-hydroxyvitamin D, parathyroid hormone,
total alkaline phosphatase, nor total testosterone levels pre-
dicted BMD or fractures at any site in our study population.
25-hydroxyvitamin D level was found to be below 20ng/mL
in 31% and 20–30ng/mL in 20% of men. In the other 49%
of men, 25-hydroxyvitamin D was above 30ng/mL.
4. Conclusions
The utility of height loss and FRAX scores as predictors
of fractures in men with prostate cancer had not been
previously studied. In our study population of older men
withprostatecancer,mostofwhomwereonADT,heightloss
was similar in men with and without compression fractures
and other osteoporosis-related fractures. In conclusion, our
study cannot suggest a threshold of height loss for which
spine X-rays or perhaps vertebral fracture assessment with
DXA should be used.
As with prior studies by Adler et al. [11]a n dS a y l o r
et al. [10], fewer men met treatment criteria when BMD
was included in FRAX score calculation. Also, fewer men
met treatment threshold for major osteoporotic fracture risk
than for hip fracture risk. Compared to Adler et al., our
study population had similar age (both with median age 77
years) and weight (85.5kg versus 88.1kg in Adler et al.) and
excluded men with fractures secondary to bone metastases
(versus 30% with bone metastases in Saylor et al.). Our
study population was 24% African-American population,
compared to 58% in Adler et al. and 5% in Saylor et al.
The utility of FRAX in predicting fracture incidence in
men with prostate cancer had not been studied previously.
An advantage of the current study is that incidence of
vertebral fracture was known due to spine radiographs,Journal of Osteoporosis 5
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so the predictive ability of FRAX scores with or without
BMD, for hip versus osteoporotic, and across ethnic groups
could be analyzed. Our study demonstrated that discovery
of incidental vertebral fractures on routine spine ﬁlms
increased the predictive ability for vertebral fracture of
all types of FRAX scores. Another novel ﬁnding was that
vertebral fracture in men with prostate cancer was better
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predicted by osteoporotic FRAX than hip FRAX. The FRAX
score (without knowledge of spine fractures) calculated with
BMD underestimated therapeutic threshold in nine men
with previously unknown spine fractures in our study. As a
result we feel that most men with prostate cancer on ADT,
and with any height loss, should have spine X-rays taken to
estimate their future fracture risk accurately.
It should be mentioned that hypogonadism is one of
the “secondary causes” in the FRAX calculator but does not
change the FRAX score if and when BMD of the femoral
neck is used in calculation. We believe that patients with
prostate cancer on ADT may be diﬀerent from “typical”
patients with hypogonadism. It is well known that patients
with prostate cancer on ADT have mostly undetectable levels
of testosterone and as the result have low estradiol levels.
Both testosterone and estradiol are imperative in preserving
bone density, quality, and in predicting the risk of future
fractures.Moreover, the eﬀectsof ADT on BMD and fracture
risk persist for years after ADT is completed [6].
The positive correlation of age and spine BMD may
be an artifact of falsely elevated BMD in lumbar spine
due to vertebral body degeneration since the group with-
out vertebral fractures had lower spine T scores (higher
spine BMD) than the group with vertebral fractures. The
signiﬁcance of the positive correlation of PSA level and
lumbar spine BMD is unclear. PSA accounted for 9% of
the variability in lumbar BMD. The mechanism by which
PSA aﬀects bone metabolism is not clearly deﬁned, but
it seems to regulate the biologic activity of parathyroid-
hormone-related protein (PTHrP). PSA speciﬁcally cleaves
PTHrP, which subsequently eliminates the ability of PTHrP
to stimulate cAMP production [14]. Moreover, PSA appears
to promote osteoblast diﬀerentiation via transcription factor
Cbfa1[15].PSApreventsboneresorptionbyinducingosteo-
protegerin activity and inhibiting the receptor activator of
nuclear factor-kB ligand (RANKL) expression on osteoblasts6 Journal of Osteoporosis
[16]. Osteoblasts produce cytokines including IL-6 that
appear to lead to androgen-independent induction of PSA
genes [17]. Increases in PSA may lead to greater production
of endothelin-1, a protein that stimulates osteoblasts and
inhibits osteoclasts in the presence of androgen-insensitive
prostatecancercells[18].Alloftheabovefactorsmayexplain
why spine BMD may be higher in men with elevated PSA.
Of note, Vitamin D levels were fairly replete in both
groups of men, those with and without fractures. This is
likely because the Urology Clinic at the Dallas VAMC often
empirically starts Calcium plus Vitamin D 500mg/250U
replacementtwicea day before we see men in the Osteoporo-
sis clinic.
Limitations of our study include the small sample size,
retrospectivedatacollection,andpossibleselectionbiasfrom
inclusion criteria. Based on prior studies discussed above,
one would expect BMD and fracture risk to be associated
with testosterone levels and the duration of ADT.
However, we did not ﬁnd it in our study. The cross-
sectional nature of the study is not optimal for evaluating
predictorsoffracturesincefracturesarealreadypresentatthe
time the variables are assessed. Our inclusion criteria likely
generated some selection bias due to the inclusion criteria
of height loss. A future study could include subjects without
height loss to compare groups with or without height loss.
The range of height loss was relatively small with over 50%
of subjects with height loss of 2 inches or less.
Including BMD of distal 1/3 radius has been shown to
increase sensitivity of DXA scans in detecting osteoporosis
[3] but is not included in routine DXA scans at DVAMC.
Going forward it would be important to study prospec-
tivelyiftheFRAXcalculatorisaprecisepredictoroffractures
in men with prostate cancer on ADT. A future study with
a prospective approach could better determine predictors of
fracture by performing spine ﬁlms at two points in time to
assess for new fractures. Further study in a larger sample is
neededtoaddressthepredictiveabilityofFRAXacrossethnic
groups.
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